The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C) (NCT05427370)
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial
🩺 Plain-English Summary (8th-Grade Level)
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- Revascularization by PCI (PROCEDURE)
- Revascularization by CABG (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Cedars-Sinai — Los Angeles, California
- Yale University — New Haven, Connecticut
- UofL Health, Inc — Louisville, Kentucky
- John Hopkins Hospital — Baltimore, Maryland
- Mayo Clinic — Rochester, Minnesota
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Medical University of Vienna — Vienna,
- Heart Institute, Medical School of the University of Sao Paulo_INCOR — São Paulo,
- University of Calgary; Libin Cardiovascular Institute — Calgary, Alberta
- Mackenzie Health Sciences Center — Edmonton, Alberta
- Fraser Health; Royal Columbian Hospital — New Westminster, British Columbia
- Providence Health — Vancouver, British Columbia
- The University of Manitoba and St. Boniface Hospital Inc. — Winnipeg, Manitoba
- Queen Elizabeth II Hospital — Halifax, Nova Scotia
- Hamilton General Hospital — Hamilton, Ontario
- London Health Sciences Center, University Hospital — London, Ontario
- Southlake Regional HC — Newmarket, Ontario
- Ottawa Heart Institute — Ottawa, Ontario
- Sunnybrook Health Sciences Center — Toronto, Ontario
- St. Michael's — Toronto, Ontario
- Toronto General Hospital — Toronto, Ontario
- Center Hospitalier Universitaire de Montreal — Montreal, Quebec
- Montreal Heart Institute — Montreal, Quebec
- Hospital Sacre-Coeur — Montreal, Quebec
- Institut de Cardiologie Quebec (QC) - Laval — Québec, Quebec
📞 Contact the Study Coordinator
Phone: (416) 480-6100
Email: stephen.fremes@sunnybrook.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Coronary Artery Disease
- Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended — Stanford, California
- Genomic Investigation of Cardiovascular Diseases — La Jolla, California
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health — Boston, Massachusetts
- A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD — Mobile, Alabama
- Firehawk Rapamycin Target Eluting Coronary Stent North American Trial — Birmingham, Alabama
- Precision PCI Registry — Gainesville, Florida
Explore by condition: All Coronary Artery Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.